Intelligent surgical targeting -

English

Press & news

October 12, 2021

Press release

Redeye initiates commissioned research on FluoGuide

Copenhagen, Denmark, 12 October 2021 – FluoGuide A/S (“FluoGuide” or the... [Read more]

October 8, 2021

Press release

FG001 is proven safe in patients undergoing surgery for cancer – a significant milestone for FluoGuide to further advance clinical development in aggressive brain cancer and in a prevalent indication

Copenhagen, Denmark, 8 October 2021 – FluoGuide A/S (“FluoGuide” or the... [Read more]

October 1, 2021

Press release

Member of the board of directors Shomit Ghose has stopped selling FluoGuide shares, after have sold 4500 shares in the period 28 to 30 September 2021

Copenhagen, Denmark, 1 October 2021 – FluoGuide A/S (“FluoGuide” or the... [Read more]

September 27, 2021

Press release

Member of the board of directors Shomit Ghose sells 3000 shares

Copenhagen, Denmark, 27 September 2021 – FluoGuide A/S (“FluoGuide” or the... [Read more]

See older news

An introduction to FluoGuide

FluoGuide provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s lead product, FG001, improves precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. The FluoGuide products is expected to reduce the suffering of patients and increase the likelihood of cure. They can also reduce costs for the health care system and thus benefit society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial.

FG001 - a unique innovation

FG001, FluoGuide’s lead product, lights up the cancer and its invasive growth into the surrounding tissue. FG001 is made of a cancer targeting molecule linked to a fluorophore. The targeting molecules bind to the urokinase-type plasminogen activator receptor (“uPAR”). uPAR is extensively expressed by cancer cells and FluoGuide utilizes this fact in the development of FG001. It is currently prepared for a proof-of-concept clinical study.

More information